Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Non-Current Liabilities: 2010-2024

Historic Total Non-Current Liabilities for Altimmune (ALT) over the last 14 years, with Dec 2024 value amounting to $5.3 million.

  • Altimmune's Total Non-Current Liabilities rose 362.49% to $27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.1 million, marking a year-over-year increase of 362.49%. This contributed to the annual value of $5.3 million for FY2024, which is 21.19% up from last year.
  • According to the latest figures from FY2024, Altimmune's Total Non-Current Liabilities is $5.3 million, which was up 21.19% from $4.4 million recorded in FY2023.
  • Altimmune's Total Non-Current Liabilities' 5-year high stood at $13.8 million during FY2020, with a 5-year trough of $4.4 million in FY2023.
  • Over the past 3 years, Altimmune's median Total Non-Current Liabilities value was $4.6 million (recorded in 2022), while the average stood at $4.8 million.
  • In the last 5 years, Altimmune's Total Non-Current Liabilities skyrocketed by 139.27% in 2020 and then crashed by 66.41% in 2022.
  • Yearly analysis of 5 years shows Altimmune's Total Non-Current Liabilities stood at $13.8 million in 2020, then fell by 1.51% to $13.6 million in 2021, then slumped by 66.41% to $4.6 million in 2022, then declined by 3.99% to $4.4 million in 2023, then rose by 21.19% to $5.3 million in 2024.